I'll be in London next week with the Endpoints crew and a great lineup of biotech experts and insiders. Join us
Well over a decade ago, I was looking over my readership numbers and decided I needed to figure out why we had such a loyal group of biotech subscribers in the UK for the pub I was editor of at the time. Well before I launched Endpoints News, I knew that the UK and Europe as a whole would play a major role in any global biotech publication.
But I just wasn’t quite sure how it all worked.
We started Endpoints with Europe and London in mind, and we’ve doubled down in the last couple of years as the Financial Times stepped in as the new majority owner. We recruited a UK-based team to sharpen our focus and continued to pay close attention to the science and the startups that are influencing the industry today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.